Potential for false positive results with antigen tests for rapid detection of SARS-CoV-2--letter to clinical laboratory staff and health care providers. | PSNet

Provide Feedback |

Register

Press Release/Announcement

Potential for false positive results with antigen tests for rapid detection of SARS-CoV-2--letter to clinical laboratory staff and health care providers.

November 11, 2020

US Food and Drug Administration: November 3, 2020.

False-positive results contribute to patient and family discomfort and harm. This announcement shares information for clinicians to improve the reliability of the COVID-19 testing process and highlights government- and staff-level actions to support effective testing.

Related Resources From the Same Author(s)

Luer Connector Misconnections: Under-Recognized but Potentially Dangerous Events.

May 28, 2019

FDA Safety Communication: use caution with implanted pumps for intrathecal administration of medicines for pain management.

November 28, 2018

ReliOn insulin syringes for use with U-100 insulin (Tyco Healthcare-Covidien).

May 24, 2015

FDA alerts patients and health care professionals of EpiPen auto-injector errors related to device malfunctions and user administration.

April 8, 2020

Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products.

January 13, 2021

Best Practices in Developing Proprietary Names for Human Prescription Drug Products Guidance for Industry.

December 23, 2020

Medication Safety During the COVID-19 Pandemic: What Have We Learned in the United States.

June 23, 2020

Drug Shortages: Root Causes and Potential Solutions.

November 13, 2019

Apotex Corp. issues voluntary nationwide recall of Enoxaparin Sodium Injection, USP due to mislabeling of syringe barrel measurement markings.

February 17, 2021

FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder.

August 5, 2020

View More

Related Resources

Wear face masks with no metal during MRI exams.

December 16, 2020

FDA advises health care professionals and patients about insulin pen packaging and dispensing.

October 28, 2020

FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder.

August 5, 2020

FDA alerts health care professionals to the temporary absence of warning statement on the vial caps of two neuromuscular blocking agents.

July 15, 2020

FDA alerts patients and health care professionals of EpiPen auto-injector errors related to device malfunctions and user administration.

April 8, 2020

FDA Safety Communication: use caution with implanted pumps for intrathecal administration of medicines for pain management.

November 28, 2018

FDA cautions about dose confusion and medication errors for antibacterial drug Zerbaxa (ceftolozane and tazobactam).

November 3, 2015

Infections associated with reprocessed flexible bronchoscopes.

September 30, 2015

Important change to heparin container labels to clearly state the total drug strength.

December 19, 2012

Hospira Carpuject pre-filled cartridges—drug alert: products may contain more than the intended fill volume.

May 30, 2012

View More

See More About The Topic

Ambulatory Clinic or Office

Health Care Providers

Diagnostic Errors

To sign up for updates or to access your subscriber preferences, please enter your email address below.

5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 427-1364